RESUMEN
In vitro cefoperazone proved more active against the tested gram-negative bacteria than either piperacillin or mezlocillin. When administered in 1 g venous bolus the antibiotic achieved high plasmatic concentrations that were still adequate after 8 hours. 33.2% was excreted by the kidneys and a considerable amount by the biliary way. Cefoperazone produced a clinical cure in 35/36 patients (97.22%). A disulfiram-like effect was noted in 18.18%.
Asunto(s)
Cefoperazona/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Bronquitis/tratamiento farmacológico , Cefoperazona/sangre , Cefoperazona/orina , Erisipela/tratamiento farmacológico , Humanos , Cinética , Mezlocilina/uso terapéutico , Piperacilina/uso terapéutico , Tonsilitis/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológicoAsunto(s)
Quimioterapia/tendencias , Mezlocilina/uso terapéutico , Animales , Bacterias Aerobias/efectos de los fármacos , Bacterias Anaerobias/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Inyecciones Intramusculares , Mezlocilina/administración & dosificación , Mezlocilina/toxicidad , Microscopía Electrónica , Ratas , Staphylococcus aureus/efectos de los fármacos , TeratógenosRESUMEN
Results obtained with sisomycin in 10 cases of purulent meningitis and 4 of bronchopulmonitis showed good tissue diffusion, together with CSF concentrations sufficient to inhibit the main aetiological agents in these forms: MIC 0.02 mg/ml for both D. pneumoniae (I-ATCC 6301) and N. meningitidis (C-ATCC 13101), i.e. liquor transfer of the antibiotic more than sufficient to handle these agents.
Asunto(s)
Bronconeumonía/tratamiento farmacológico , Gentamicinas/uso terapéutico , Meningitis/tratamiento farmacológico , Infecciones Meningocócicas/tratamiento farmacológico , Infecciones Neumocócicas/tratamiento farmacológico , Sisomicina/uso terapéutico , Adolescente , Adulto , Anciano , Bacterias/efectos de los fármacos , Niño , Evaluación de Medicamentos , Femenino , Humanos , Inyecciones Intramusculares , Inyecciones Intravenosas , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Sisomicina/efectos adversos , Sisomicina/metabolismoRESUMEN
A controlled double-blind biometric and an open clinical trial were conducted to determine the therapeutic effectiveness of a new equal-dose w/w association of amoxicillin and flucloxacillin. The following conclusions were drawn. Both antibiotics were present in high serum levels; those of flucloxacillin were higher and more persistent. Analysis of variance on 89 patients pointed to the superiority of the association by comparison with amoxicillin alone. The clinical study made it clear that the broad and complementary spectrum of the association, its synergy, absence of toxicity and good gastric tolerance make it a valuable and effective therapeutic aid, also in presence of germs that produce beta-lactase.